Make your products visible globally with Elite Membership.
I agree to the terms and conditions
Existing User?
Sign In with Email
Remember Me Forgot Password?
New User?
Enter your registered Email ID to get reset password.
Elite Member
Individual Register
Saredutant is a drug which acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research and development projects, among which was saredutant for the treatment of major depressive disorder.
Sarmazenil is a drug from the benzodiazepine family. It acts as a partial inverse agonist of benzodiazepine receptors, meaning that it causes the opposite effects to most benzodiazepine drugs, and instead acts as an anxiogenic and convulsant. It is used in veterinary medicine to reverse the effects of benzodiazepine sedative drugs in order to rapidly re-awaken anaethetised animals.
Semorphone is an opiate analogue that is an N-substituted derivative of oxymorphone. It is a partial agonist at μ-opioid receptors. It is around twice the potency of morphine, but with a ceiling effect on both analgesia and respiratory depression which means that these effects stop becoming any stronger after a certain maximum dose.
Sertindole is an antipsychotic medication. It was developed by the Danish pharmaceutical company H. Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative.
Sertraline is a selective serotonin uptake inhibitor that is used in the treatment of depression.It is believed that sertraline inhibits reuptake of serotonin at the neuronal membrane. SSRIs have less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because of decreased binding to histamine, acetylcholine, and norepinephrine receptors.Symptoms of toxicity include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome
Setazindol is an anorectic. It was never marketed.
Sildenafil (in citrate form), sold under the names Viagra, Revatio and under various other names, is a drug used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH), developed by the pharmaceutical company Pfizer. Its primary competitors on the market are tadalafil (Cialis), and vardenafil (Levitra).
Sinomenine is an alkaloid found in the root of the climbing plant Sinomenium acutum which is native to Japan and China. It is traditionally used in herbal medicine in these countries, as a treatment for rheumatism and arthritis. However its analgesic action against other kinds of pain is limited. It is a morphinan derivative, related to opioids such as levorphanol and the non-opioid cough suppressant dextromethorphan. Its anti-rheumatic effects are thought to be primarily mediated via release of histamine, but other effects such as inhibition of prostaglandin, leukotriene and nitric oxide synthesis may also be involved.
Stanozolo is a synthetic anabolic steroid derived from testosterone. The drug has a high oral bioavailability, due to a C17 α-alkylation which allows the hormone to survive first-pass liver metabolism when ingested. It is usually considered a safer choice for female bodybuilders in that its anabolic effects predominate over its androgenic effects, although virilization and masculinization are still very common even at low doses. It has been used in both animal and human patients for a number of conditions. In humans, it has been demonstrated to be successful in treating anaemia and hereditary angioedema. Veterinarians may prescribe the drug to improve muscle growth, red blood cell production, increase bone density and stimulate the appetite of debilitated or weakened animals.
Sultopride is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. It acts as a selective D2 and D3 receptor antagonist. It has also been shown to have clinically-relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.
Stay updated with the latest chemical industry trends and innovations.
Verification Code has been sent to
Please enter the Verification Code below to verify your Email Address.If you cannot see the email from "noreply@worldofchemicals.com" in your inbox,make sure to check your SPAM Folder